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medicine? The answer: focused, gender-specific, cardiovascular
clinical research.
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REPLY
In the gender subgroup analysis of the CURE (Clopidogrel in
Unstable Angina to Prevent Recurrent Events) trial data, we
observed that fewer women across all Thrombolysis In Myocardial
Infarction (TIMI) risk strata underwent coronary angiography
compared to men (1). However, among women who did have
significant coronary artery disease (CAD), an equal proportion
went on to have coronary revascularization compared to men. We
also noted, however, that women in the high-risk acute coronary
syndromes (ACS) group were significantly more likely to have
refractory angina or be readmitted to a hospital with recurrent
angina as compared to men. Dr. Kessler is correct that the
differences in revascularization rates could not account for the
difference in refractory ischemia/rehospitalization rates we ob-
served. However, if women were equally as likely to have coronary
angiograms as men, then more women with significant CAD may
have been identified. Subsequent revascularization in this high-risk
group may have equalized the rates of refractory ischemia between
women and men.
However, we recognize that our association represents a
subgroup analysis, which at best can raise a hypothesis but
cannot confirm whether it is true. Like Dr. Kessler, we also
advocate sex- and gender-based research in cardiovascular
disease using sufficient sample sizes and methodology to be
confirmatory.
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Troponin Trumps Common Sense
The state-of-the-art review of biomarkers in acute cardiac
disease by Drs. Jaffe, Babuin, and Apple is thoughtful and
timely (1). My concern, shared by many cardiologists, is that
troponin testing has gotten out of hand. Most cardiologists have
been asked to see a patient (often urgently) found to have a
mildly elevated troponin when the test was ordered reflexively—
regardless of the patient’s presenting complaints or past history.
Cardiologists on hospital services are tripping over troponin every
day. The most challenging situation is when a patient presents
with a serious (even life-threatening) noncardiac condition, and
one or more doctors involved in their care gets distracted by an
incidental mild troponin elevation. Occasionally, this leads to a
sudden obsession over one test result, a phenomenon I call
“troponin trumps common sense.”
Several problems are associated with the uninformed use of this
sensitive assay. The authors present information about the appro-
priate use of troponin testing that should be actively diffused into
practice. They write, “Because of the sensitivity of cTn [cardiac
troponin], elevations are common in patients with a large number
of acute and chronic cardiovascular diseases. It is up to the clinician
to decide whether the presentation is one of acute ischemia.”(1)
Table 2 (1) lists about two dozen situations where “elevations of
troponin in the absence of overt ischemic heart disease” occur.
Admittedly, most patients presenting with an acute coronary
syndrome (ACS) also have one or more of the conditions listed.
This is where clinical judgment counts. The patients I am
describing do not present with chest pain, dyspnea, or other
symptoms and signs, or an electrocardiogram suggesting an acute
cardiovascular problem.
Consider the cost of all the unnecessary stress tests ordered,
coronary angiograms performed, and anti-platelet agents pre-
scribed for mild troponin elevations when the clinical situation
makes an acute cardiovascular problem very unlikely. The casual
use of the phrase non–ST-segment elevation myocardial infarc-
tion (NSTEMI) when the mild troponin elevation is not, in
fact, due to atherosclerotic coronary artery disease, creates its
own legacy. Think twice before attaching the NSTEMI label to
a patient with a mild troponin elevation much more likely to be
due to one or more of the conditions outlined by the authors in
Table 2 (1).
It is useful to draw an analogy between mild troponin elevations
and nonspecific ST-T changes on an electrocardiogram. I suggest
using the descriptive phrase “nonspecific mild troponin elevation”
if there is no compelling evidence to support a diagnosis of an ACS
and in patients with chronic cardiovascular disease or noncardiac
diseases. Doctors do not feel compelled to request an urgent
cardiology consult on every patient with nonspecific ST-T changes
on an electrocardiogram in the absence of any cardiac symptoms or
history of cardiac disease. Rather than allowing troponin to trump
common sense, we should inject more common sense into the
process of ordering a troponin level in the first place.
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Biomarkers in Acute Cardiac Disease
In their state-of-the-art paper on biomarkers in acute cardiac
disease (1), Dr. Jaffe and colleagues list creatine kinase-MB
(CK-MB) as a “potentially outdated marker.” However, CK-MB
has a specific utility in the diagnosis of reinfarction (2), and it
cannot be replaced by the cardiac troponins for this purpose. By
following up the time course of rise and fall of CK-MB, an
interruption in the progressive decline in the level of the biomarker
(to levels below upper reference limit) can be detected (2–4).
Re-elevations in CK-MB by more than 50%, can be used to
diagnose re-infarctions as early as 18 h after the index event (2).
Both cardiac troponin T (cTnT) and cardiac troponin I (cTnI) on
the other hand are continuously released from degenerating con-
tractile apparatus in necrotic cardiomyocytes and may show per-
sistent elevations, 7 to 10 days in the case of cTnI and up to 10 to
14 days in the case of cTnT, after the index event (2). The
protracted time course of kinetic release of cTnI and cTnT limit
their ability to diagnose reinfarction even several days after the
index ST-segment elevation myocardial infarction (STEMI) be-
cause the cardiac troponin levels will still be on the rise during this
period as a result of their normal kinetics, and it is not possible to
be sure whether the rise is due to a re-infarction or not. It is
because of this important difference in the kinetics between
CK-MB, which shows a rapid rise and fall, and the troponins, the
American College of Cardiology/American Heart Association
Practice guidelines for STEMI specifically state that CK-MB is
superior for diagnosing reinfarction (2). This is very relevant as
recurrent chest pain is a common complaint of patients admit-
ted for myocardial ischemia and CK-MB plays a vital role in the
further evaluation of this complaint.
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REPLY
Drs. Fye, Nagajothi, and Trivedi raise important issues that we are
pleased to address.
One that many of us have tried to reinforce for years is that
elevations of biomarkers of cardiac injury are not synonymous with
myocardial infarction (1). This is especially important for cardiac
troponin which, because it is more sensitive than creatine kinase
MB (CKMB), detects cardiac injury in many situations which are
not due to primary coronary abnormalities. Thus, many patients
with elevations do not require the extensive workups Dr. Fye
correctly indicates can occur if one obviates common sense. Some
may need an evaluation for pulmonary embolism or myocarditis
and some only watchful waiting. Some of this can occur in the
outpatient setting in our view, but we often see cardiologists
assume that once the patient is discharged that they can forget
about elevations. Neglecting such a potent risk factor for mortality
is not good common sense either. Regardless of the etiology,
elevations of troponin are indicative of significant cardiovascular
disease and usually are associated with an adverse prognosis in the
short term (2) and over time once recovery occurs (3) and in those
who are more compensated (4). When such elevations occur in
critically ill individuals, first efforts should be focused on the
primary disease process which very often is the stimulus for the
cardiac injury. Additional work is necessary to distinguish when we
as cardiologists should address cardiac issues acutely over and
above treating the underlying disease state. Many of us are actively
involved in trying to define such subsets at present. Whether or not
acute intervention is needed, it is clear from most studies that
elevations of troponin also predict adverse long term events (3,4).
Thus, those who were critically ill and recover and those in whom
“incidental” elevations of troponin were detected, require careful
evaluation. That could mean an evaluation for ischemic heart
disease but as Dr. Fye suggests, it is prudent to consider other
etiologies for elevations as well.
It is also good common sense to upgrade our clinical judgment
periodically. It is thus prudent in considering the possibility in a
given patient of ischemic heart disease to take note of information
concerning the lack of perfection of the angiogram, (5) differences
in the way in which women present with infarction, (6) and the
recent article in the Journal of the American College of Cardiology
suggesting the high frequency of unrecognized myocardial infarc-
tions detected in older individuals by MRI (7).
The issue of reinfarction is one where we have used common
sense. The state of the art and guidelines are not the same. The
later are often much more conservative. It was presumed in the
initial studies, that increases in CKMB post-infarction were
indicative of reinfarction. There was no independent validation of
that. There has been no validation of the use of increases on the
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